Changes to the Code
H.R. 4273 · Over-the-Counter Monograph Drug User Fee Amendments · Reported The text a committee sent back to its chamber, often with changes, recommending a vote.
Reported by committee · step 2 of 5
21 U.S.C. § 379j–71 Definitions
4 changes the bill asks for here, 1 carried out
- Not carried out:
in clause (v), by striking
; or
and inserting a semicolon;
“; or” isn't in § 379j–71(9)(A)(v) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“; or” not found in /us/usc/t21/s379j–71/9/A/v - Not carried out:
by striking
addition
and insertingthe addition
; andThe law already reads this way: § 379j–71(9)(A)(vi) already has “the addition”.
Technical detail
already reads “the addition” in /us/usc/t21/s379j–71/9/A/vi - Carried out:
by striking the period and inserting
; or
; and - Not carried out:
by adding at the end the following:
(vii) the addition or modification of a testing procedure applicable to one or more OTC monograph drugs, provided that such additional or modified testing procedure reflects a voluntary consensus standard with respect to pharmaceutical quality that is— (I) established by a …
The law already reads this way: § 379j–71(9)(A)(vii) is already as the bill would have it.
Technical detail
already there: /us/usc/t21/s379j–71/9/A/vii reads as the bill would have it
2 of the 4 changes this bill asks for here are already in the law as it stands, and were not made a second time. The bill, or another making the same changes, has probably become law since.
§ 379j–71(9)(A)“Tier 2 OTC monograph order request” means…(v)–(vii)
Start of § 379j–71 to (9)(A)(iv) unchanged ·
(v) a change to ingredient nomenclature to align with nomenclature of a standards-setting organization;
(vi) the addition of an interchangeable term in accordance with section 330[struck: .1][inserted: ;] [inserted: or1 ]of title 21, Code of Federal Regulations (or any successor regulations); or
(vii) the addition or modification of a testing procedure applicable to one or more OTC monograph drugs, provided that such additional or modified testing procedure reflects a voluntary consensus standard with respect to pharmaceutical quality that is—
(I) established by a national or international standards development organization; and
Rest of § 379j–71 unchanged ·
21 U.S.C. § 379j–72 Authority to assess and use OTC monograph fees
26 changes the bill asks for here, 8 carried out
- Not carried out:
by striking
on December 31 of the fiscal year or at any time during the preceding 12-month period
and insertingat any time during the applicable period specified in clause (ii) for a fiscal year
;“on December 31 of the fiscal year or at any time during the preceding 12-month period” isn't in § 379j–72(a)(1)(A) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“on December 31 of the fiscal year or at any time during the preceding 12-month period” not found in /us/usc/t21/s379j–72/a/1/A - Not carried out:
by striking Each person and inserting the following:(i) Assessment of fees.— Each person; and
The law already reads this way: § 379j–72(a)(1)(A)(i) already sets these words apart as their own provision.
Technical detail
already: /us/usc/t21/s379j–72/a/1/A/i holds the words already - Not carried out:
by adding at the end the following:
(ii) Applicable period.— For purposes of clause (i), the applicable period is— (I) for fiscal year 2026, the 12-month period ending on December 31, 2025; (II) for fiscal year 2027, the 9-month period ending on September 30, 2026; and (III) for fiscal year 2028 and each …
The law already reads this way: § 379j–72(a)(1)(A)(ii) is already as the bill would have it.
Technical detail
already there: /us/usc/t21/s379j–72/a/1/A/ii reads as the bill would have it - Carried out:
in subparagraph (B)(i), by amending subclause (I) to read as follows:
(I) has ceased all activities related to OTC monograph drugs prior to— (aa) for purposes of fiscal year 2026, January 1, 2025; (bb) for purposes of fiscal year 2027, January 1, 2026; and (cc) for purposes of fiscal year 2028 and each subsequent fiscal year, October 1 of the preceding fiscal year; and; and
- Carried out:
by amending subparagraph (D) to read as follows:
(D) Due date.— (i) Fiscal year 2026.— For fiscal year 2026, the facility fees required under subparagraph (A) shall be due on the later of— (I) the first business day of June of such year; or (II) the first business day after the enactment of an appropriations Act providing for …
- Carried out:
Section 744M(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j–72(b)) is amended to read as follows:
(b) Fee revenue amounts.— (1) In general.— For each of the fiscal years 2026 through 2030, fees under subsection (a)(1) shall be established to generate a total facility fee revenue amount equal to the sum of— (A) the annual base revenue for the fiscal year (as determined under …
- Not carried out:
by striking
subsection (b)(2)(B)
and insertingsubsection (b)(1)(B)
; and“subsection (b)(2)(B)” isn't in § 379j–72(c)(1)(A) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“subsection (b)(2)(B)” not found in /us/usc/t21/s379j–72/c/1/A - Not carried out:
by striking
fiscal year 2022 and each subsequent fiscal year
and insertingeach fiscal year
;“fiscal year 2022 and each subsequent fiscal year” isn't in § 379j–72(c)(1)(A) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“fiscal year 2022 and each subsequent fiscal year” not found in /us/usc/t21/s379j–72/c/1/A - Not carried out:
in subparagraph (B), by striking fiscal year 2022 and all that follows through the period at the end and inserting the following:
(i) for fiscal year 2026— (I) the fee for fiscal year 2025 under subsection (a)(2); and (II) the inflation adjustment percentage under subparagraph (C); and (ii) for each of fiscal years 2027 through 2030— (I) the applicable fee under subsection (a)(2) for the preceding fiscal …
We can't read how this instruction is worded yet, so it isn't shown in the text.
Technical detail
no-pattern: striking QTEXT and all that follows through the period at the end and inserting the following: QCONTENT; and - Not carried out:
in the matter preceding clause (i), by inserting
the sum of
afteris equal to
;The law already reads this way: § 379j–72(c)(1)(C) already has “the sum of”.
Technical detail
already reads “the sum of” at that place in /us/usc/t21/s379j–72/c/1/C - Carried out:
by striking clause (i);
- Not carried out:
by redesignating subclauses (I) and (II) of clause (ii) as clauses (i) and (ii), respectively, and adjusting the margins accordingly;
We can't read how this instruction is worded yet, so it isn't shown in the text.
Technical detail
no-pattern: redesignating subclauses (X) and (X) of clause (X) as clauses (X) and (X), respectively, and adjusting the margins accordingly; - Not carried out:
by striking
(ii) for each of fiscal years 2024 and 2025, the sum of—
; and“(ii) for each of fiscal years 2024 and 2025, the sum of—” isn't in § 379j–72(c)(1)(C) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“(ii) for each of fiscal years 2024 and 2025, the sum of—” not found in /us/usc/t21/s379j–72/c/1/C - Not carried out:
in clause (ii), as so redesignated, by striking
Washington-Baltimore, DC–MD–VA–WV
and insertingWashington–Arlington–Alexandria–DC–VA–MD–WV
;“Washington-Baltimore, DC–MD–VA–WV” isn't in § 379j–72(c)(1)(C)(ii) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“Washington-Baltimore, DC–MD–VA–WV” not found in /us/usc/t21/s379j–72/c/1/C/ii - Not carried out:
by striking
fiscal year 2021 and subsequent fiscal years
and insertingeach fiscal year
;“fiscal year 2021 and subsequent fiscal years” isn't in § 379j–72(c)(2)(A) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“fiscal year 2021 and subsequent fiscal years” not found in /us/usc/t21/s379j–72/c/2/A - Not carried out:
by striking
subsections (b)(1)(B) and (b)(2)(C)
and insertingsubsection (b)(1)(C)
; and“subsections (b)(1)(B) and (b)(2)(C)” isn't in § 379j–72(c)(2)(A) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“subsections (b)(1)(B) and (b)(2)(C)” not found in /us/usc/t21/s379j–72/c/2/A - Not carried out:
by striking
the number of weeks specified in subparagraph (B)
and inserting10 weeks
;“the number of weeks specified in subparagraph (B)” isn't in § 379j–72(c)(2)(A) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“the number of weeks specified in subparagraph (B)” not found in /us/usc/t21/s379j–72/c/2/A - Carried out:
by striking subparagraph (B);
- Carried out:
by redesignating subparagraphs (C) and (D) as subparagraphs (B) and (C), respectively; and
- Not carried out:
in subparagraph (C), as so redesignated, by striking
paragraph (4) establishing
and insertingparagraph (5) publishing
;The bill points to subparagraph (C) of § 379j–72(c)(2), which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.
Technical detail
target not found: no subparagraph (C) in /us/usc/t21/s379j–72/c/2 - Not carried out:
in the matter preceding subparagraph (A), by striking
subsection (b)(2)(D)
and insertingsubsection (b)(1)(D)
; and“subsection (b)(2)(D)” isn't in § 379j–72(c)(3) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“subsection (b)(2)(D)” not found in /us/usc/t21/s379j–72/c/3 - Carried out:
by striking subparagraphs (A) through (E) and inserting the following:
(A) $135,000 for fiscal year 2026; (B) $300,000 for fiscal year 2027; (C) $55,000 for fiscal year 2028; (D) $30,000 for fiscal year 2029; and (E) $0 for fiscal year 2030.; and
- Carried out:
by striking paragraph (4) and inserting the following:
(4) One-time facility fee workload adjustment.— (A) In general.— In addition to the adjustments under paragraphs (1), (2), and (3), the Secretary may further increase the fee revenues and fees through a one-time adjustment made for fiscal year 2028, 2029, or 2030, in accordance …
- Not carried out:
in the subparagraph heading, by striking
in subsequent years
; and“in subsequent years” isn't in § 379j–72(f)(2)(D) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“in subsequent years” not found in /us/usc/t21/s379j–72/f/2/D - Not carried out:
by striking
(after fiscal year 2021)
; and“(after fiscal year 2021)” isn't in § 379j–72(f)(2)(D) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“(after fiscal year 2021)” not found in /us/usc/t21/s379j–72/f/2/D - Not carried out:
in paragraph (3), by striking
2021 through 2025
and inserting2026 through 2030
.“2021 through 2025” isn't in § 379j–72(f)(3) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“2021 through 2025” not found in /us/usc/t21/s379j–72/f/3
3 of the 26 changes this bill asks for here are already in the law as it stands, and were not made a second time. The bill, or another making the same changes, has probably become law since.
§ 379j–72(a)(1)Facility fee(B)–(D)
Start of § 379j–72 to (a)(1)(B)(i)(II) unchanged ·
(ii) Contract manufacturing organizations The amount of the fee for a contract manufacturing organization facility shall be equal to two-thirds of the amount of the fee for an OTC monograph drug facility that is not a contract manufacturing organization facility.
(C) Amount The amount of fees established under subparagraph (A) shall be established under subsection (c).
(D) Due date[inserted: .—]
(i) Fiscal year 2026[inserted: .—] For fiscal year 2026, the facility fees required under subparagraph (A) shall be due on the later of—
(I) the first business day of June of such year; or
(II) the first business day after the enactment of an appropriations Act providing for the collection and obligation of fees under this section for such year.
(ii) Fiscal year 2027[inserted: .—] For fiscal year 2027, the facility fees required under subparagraph (A) shall be due—
(I) in a first installment representing 50 percent of such fee, on the later of—
§ 379j–72(a)(1)(D)Due date.—(ii)–(iii)
(a)(1)(D)(ii)(I)(aa)–(II) unchanged ·
(aa) February 1, 2027; or
(bb) if an appropriations Act described in subclause (I)(bb) is not in effect on February 1, 2027, the first business day after enactment of such an appropriations Act.
(iii) Subsequent fiscal years[inserted: .—] For fiscal year 2028 and each subsequent fiscal year, the facility fees required under subparagraph (A) shall be due on the later of—
(I) the first business day on or after October 1 of the fiscal year; or
§ 379j–72(a)–(b)
(a)(1)(D)(iii)(II)–(3)(A) unchanged ·
(B) Disputes concerning fees To qualify for the return of a fee claimed to have been paid in error under paragraph (1) or (2), a person shall submit to the Secretary a written request justifying such return within 180 calendar days after such fee was paid.
(4) Notice Within the timeframe specified in subsection (c), the Secretary shall publish in the Federal Register the amount of the fees under paragraph (1) for such fiscal year.
(b) Fee revenue amounts[inserted: .—]
(1) In general[inserted: .—] For each of the fiscal years 2026 through 2030, fees under subsection (a)(1) shall be established to generate a total facility fee revenue amount equal to the sum of—
(A) the annual base revenue for the fiscal year (as determined under paragraph (2));
§ 379j–72(b)–(c)
(b)(1)(B)–(E) unchanged ·
(iii) $854,000 for fiscal year 2028; and
(F) in the case of a fiscal year for which the Secretary applies the one-time facility fee workload adjustment under subsection (c)(4), the dollar amount equal to such adjustment.
(2) Annual base revenue[inserted: .—] For purposes of paragraph (1), the dollar amount of the annual base revenue for a fiscal year shall be—
(A) for fiscal year 2026, the dollar amount of the total revenue amount established for fiscal year 2025 under this subsection as in effect on the day before [struck: November][inserted: the] [struck: 12,][inserted: date] [struck: 2025][inserted: of enactment of the Over-the-Counter Monograph Drug User Fee Amendments], not including any adjustments made for such fiscal year 2025 under subsection (c)(2), as so in effect; and
(B) for fiscal years 2027 through 2030, the dollar amount of the total revenue amount established under this subsection for the previous fiscal year, not including any adjustments made for such previous fiscal year under subsection (c)(2) or (c)(3).
(c) Adjustments; annual fee setting
§ 379j–72(c)Adjustments; annual fee setting(1)–(4)
(c)(1) unchanged ·
(II) the inflation adjustment percentage under subparagraph (C).
(C) Inflation adjustment percentage The inflation adjustment percentage under this subparagraph for a fiscal year is equal to the sum of—
[struck: (i)] [struck: the average annual percent change in the cost, per full-time equivalent position of the Food and Drug Administration, of all personnel compensation and benefits paid with respect to such positions for the first 3 years of the preceding 4 fiscal years, multiplied by the proportion of personnel compensation and benefits costs to total costs of OTC monograph drug activities for the first 3 years of the preceding 4 fiscal years; and]
(ii) the average annual percent change that occurred in the Consumer Price Index for urban consumers (Washington–Arlington–Alexandria–DC–VA–MD–WV; Not Seasonally Adjusted; All items; Annual Index) for the first 3 years of the preceding 4 years of available data multiplied by the proportion of all costs other than personnel compensation and benefits costs to total costs of OTC monograph drug activities for the first 3 years of the preceding 4 fiscal years.
(2) Operating reserve adjustment
(A) In general For each fiscal year, for purposes of subsection (b)(1)(C), the Secretary may, in addition to adjustments under paragraph (1), further increase the fee revenue and fees if such an adjustment is necessary to provide operating reserves of carryover user fees for OTC monograph drug activities for not more than 10 weeks.
[struck: (B)] [struck: Decrease] [struck: If the Secretary has carryover balances for such process in excess of 10 weeks of the operating reserves referred to in subparagraph (A), the Secretary shall decrease the fee revenue and fees referred to in such subparagraph to provide for not more than 10 weeks of such operating reserves.]
[struck: (C)] [inserted: (B)] Rationale for adjustment If an adjustment under this paragraph is made, the rationale for the amount of the increase or decrease (as applicable) in fee revenue and fees shall be contained in the annual Federal Register notice under paragraph (5) publishing fee revenue and fees for the fiscal year involved.
(3) Additional direct cost adjustment The Secretary shall, in addition to adjustments under paragraphs (1) and (2), further increase the fee revenue and fees for purposes of subsection (b)(1)(D) by an amount equal to—
(A) $135,000 for fiscal year 2026;
(B) $300,000 for fiscal year 2027;
(C) $55,000 for fiscal year 2028;
(D) [inserted: $30,000 for fiscal year 2029; and]
[struck: (D)] [struck: $30,000 for fiscal year 2029; and]
(E) $0 for fiscal year 2030.
(4) One-time facility fee workload adjustment[inserted: .—]
(A) In general[inserted: .—] In addition to the adjustments under paragraphs (1), (2), and (3), the Secretary may further increase the fee revenues and fees through a one-time adjustment made for fiscal year 2028, 2029, or 2030, in accordance with this paragraph.
(B) Adjustment described[inserted: .—]
(i) Conditions for adjustment[inserted: .—] An adjustment under this paragraph may be made for a fiscal year only if—
(I) an adjustment under this paragraph had not been made for any prior fiscal year;
(II) the average number of OTC monograph drug facilities subject to a facility fee under subsection (a)(1) over the period of the preceding 3 fiscal years exceeds 1,625; and
(III) with respect to facilities described in subclause (II), the average number of such facilities (expressed as a percentage) that appeared on the arrears lists pursuant to subsection (e)(1)(A)(i) over the period of the preceding 3 fiscal years is less than 30 percent.
(ii) Amount of adjustment[inserted: .—] An adjustment under this paragraph for a fiscal year shall equal the product of—
(I) the total facility revenue amount determined under subsection (b) for the fiscal year, exclusive of the adjustment under this paragraph for such fiscal year; and
(II) the excess facility percentage described in clause (iii).
(iii) Excess facility percentage[inserted: .—] The excess facility percentage described in this clause is—
(I) the amount by which the average number of OTC monograph drug facilities subject to a facility fee under subsection (a)(1) over the preceding 3 fiscal years exceeds 1,625; divided by
Rest of § 379j–72 unchanged ·
21 U.S.C. § 355h Regulation of certain nonprescription drugs that are marketed without an approved drug application
The law already reads the way this bill would leave it here. The bill, or another that makes the same changes, has probably become law since.
The bill's words for this section
- Not carried out:
Section 505G(h) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355h(h)) is amended by striking
sponsors or requestors
and insertingsponsors, requestors, or organizations nominated by sponsors or requestors to represent their interests in a proceeding
.The law already reads this way: § 355h(h) already has “sponsors, requestors, or organizations nominated by sponsors or requestors to represent their interests in a proceeding”.
Technical detail
already reads “sponsors, requestors, or organizations nominated by sponsors or requestors to represent their interests in a proceeding” in /us/usc/t21/s355h/h - Not carried out:
Section 505G(b)(2)(A)(iv)(III) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355h(b)(2)(A)(iv)(III)) is amended by striking
requestors
and insertingsponsors or requestors
.The law already reads this way: § 355h(b)(2)(A)(iv)(III) already has “sponsors or requestors”.
Technical detail
already reads “sponsors or requestors” in /us/usc/t21/s355h/b/2/A/iv/III
21 U.S.C. § 379j–73 Reauthorization; reporting requirements
The bill's words for this section
- Not carried out:
by striking
Beginning with fiscal year 2021, and not later than 120 calendar days after the end of each fiscal year thereafter
and insertingNot later than 120 calendar days after the end of each fiscal year
; and“Beginning with fiscal year 2021, and not later than 120 calendar days after the end of each fiscal year thereafter” isn't in § 379j–73(a) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“Beginning with fiscal year 2021, and not later than 120 calendar days after the end of each fiscal year thereafter” not found in /us/usc/t21/s379j–73/a - Not carried out:
by striking
section 3861(b) of the CARES Act
and insertingsection 2 of the Over-the-Counter Monograph Drug User Fee Amendments
;“section 3861(b) of the CARES Act” isn't in § 379j–73(a) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“section 3861(b) of the CARES Act” not found in /us/usc/t21/s379j–73/a - Not carried out:
in subsection (b), by striking
fiscal year 2021 and each subsequent fiscal year
and insertingeach fiscal year
; and“fiscal year 2021 and each subsequent fiscal year” isn't in § 379j–73(b) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“fiscal year 2021 and each subsequent fiscal year” not found in /us/usc/t21/s379j–73/b - Not carried out:
in subsection (d), by striking
2025
each place it appears and inserting2030
.“2025” isn't in § 379j–73(d) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“2025” not found in /us/usc/t21/s379j–73/d